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Dongsheng Xu‡1, Florencia Meyer‡2, Erica Ehlers‡, Laura Blasnitz‡3, and Luwen Zhang‡§4
From the ‡School of Biological Sciences and §Nebraska Center for Virology, University of Nebraska, Lincoln, Nebraska 68588
The cellular interferon regulatory factor-4 (IRF-4), which is a
member of IRF family, is involved in the development of multiple myeloma and Epstein-Barr virus (EBV)-mediated transformation of B lymphocytes. However, the molecular mechanism
of IRF-4 in cellular transformation is unknown. We have found
that knockdown of IRF-4 leads to high expression of IRF-5, a
pro-apoptotic member in the IRF family. Overexpression of
IRF-4 represses IRF-5 expression. Reduction of IRF-4 leads to
growth inhibition, and the restoration of IRF-4 by exogenous
plasmids correlates with the growth recovery and reduces IRF-5
expression. In addition, IRF-4 negatively regulates IRF-5 promoter reporter activities and binds to IRF-5 promoters in vivo
and in vitro. Knockdown of IRF-5 rescues IRF-4 knockdownmediated growth inhibition, and IRF-5 overexpression alone is
sufficient to induce cellular growth inhibition of EBV-transformed cells. Therefore, IRF-5 is one of the targets of IRF-4, and
IRF-4 regulates the growth of EBV-transformed cells partially
through IRF-5. This work provides insight on how IRFs interact
with one another to participate in viral pathogenesis and
transformation.

Interferon regulatory factors (IRFs)5 are a small family of
transcription factors that have multiple functions. The hallmark of these factors is a conserved N-terminal DNA-binding
domain, which mediates binding to consensus or similar DNA
sequences such as interferon-stimulated response element
(ISRE) and IRF-binding elements. The C-terminal portion is
variable and defines biological functions (1–3). Currently, the
IRF family has nine members with a variety of functions including, but not limited to, apoptosis, oncogenesis, host defense,
viral latency, and immune response (2– 4).
Epstein-Barr virus (EBV) is a human herpesvirus, belonging
to the gamma herpesvirus family. EBV almost certainly triggers
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two fatal cancers without the necessity for cofactors as follows:
AIDS-associated central nervous system lymphoma and posttransplantation lymphoproliferative disorder (5). In addition,
EBV is associated with many different human malignancies,
including Burkitt lymphoma, nasopharyngeal carcinoma,
Hodgkin lymphoma, and several other diseases (6). EBV transforms adult primary B cells into continually growing lymphoblastoid cell lines and concomitantly establishes type III latency
in vitro (5).
IRF-4 is involved in the pathogenesis of EBV-mediated transformation of B lymphocytes and plays an essential role in cell
growth of multiple myeloma cells (7, 8). IRF-4 represses expression of certain genes implicated in the mitotic checkpoint, DNA
repair, apoptosis, metastasis, and immune recognition and may
provide important functions critical to the emergence of adult
T cell leukemia (9 –11). Interestingly, IRF-4 alone is apparently
not sufficient for oncogenesis in transgenic mice overexpressing IRF-4 in lymphocytes (12), suggesting that additional factors are required for the oncogenic activity of IRF-4 in vivo.
Moreover, the cellular environments may determine its specific
functions. IRF-4 promotes cellular proliferation in EBV-transformed cells and in multiple myeloma, but in early B cell development, IRF-4 is considered as a tumor suppressor (13). IRF-4
interacts with many different cellular factors, which may determine its biological functions in various cellular environments.
Other than oncogenesis, IRF-4 is essential for the function and
homeostasis of both mature B and T lymphocytes (14). Furthermore, IRF-4 is critical for pre-B-to-B transition and development of certain dendritic cells (15, 16).
IRF-5 is involved in Toll-like receptor-mediated activation of
innate and adaptive immune systems (17). Overexpression of
IRF-5 modulates the expression of some genes in apoptotic
pathways along with multiple cell cycle regulatory factors (18).
Although WT p53 stimulates expression of IRF-5 (19), the
pro-apoptotic and cell cycle regulatory effects of IRF-5 are completely independent of p53. The ectopic IRF-5 sensitizes p53proficient and p53-deficient cancer cells to DNA damageinduced apoptosis (20). IRF-5 is selectively involved in
apoptosis but not in cell cycle arrest in vivo (21, 22).
Previously, we have found that IRF-4 is a critical factor in the
EBV-transformation process in vitro (7). To address this possible mechanism, we have identified IRF-5 as a cellular target of
IRF-4; knockdown of IRF-4 leads to high expression of IRF-5,
and overexpression of IRF-4 represses IRF-5. IRF-5 overexpression alone is sufficient to induce growth inhibition, and knockdown of IRF-5 rescues IRF-4 knockdown-mediated growth
inhibition. Therefore, IRF-4 regulates cell growth partially
through IRF-5 in EBV transformation.
JOURNAL OF BIOLOGICAL CHEMISTRY
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MATERIALS AND METHODS
Plasmids and Antibodies—Expression plasmid of IRF-4,
F-IRF-4, was made by PCR with pCEP-IRF-4 as a template and
cloned into 3⫻FLAG-Myc-CMV expression vector (Sigma).
pCEP-IRF-4 was a gift from Alessandra B. Pernis. IRF-5 PV1
and PV3 luciferase reporter constructs were gifts from Dr.
Barnes. IRF-5 expression plasmid (v4) was a gift from Dr. Paula
Pitha. The mPV3-luc has the same mutations in the ISRE
region, as described previously (23). The mutations were introduced into the PV3 promoter reporter construct using the
QuikChange威 site-directed mutagenesis kit (Stratagene) following the recommended conditions. shLuc and shIRF-41, -42,
and -43 were described previously (7). shIRF-4 was the mixture
of shIRF-41, -42, and -43 in a 1:1:1 ratio. The shIRF4UTR5
(target sequence (5⬘-AGGGCGAGTGCAGAGCAGA-3⬘)
and shIRF4UTR3 (5⬘-CAGATGAGCTTATTTCAAA-3⬘),
shIRF-51 (5⬘-GGTCAACGGGGAAAAGAAA-3⬘), shIRF-52
(5⬘-AGGAAGAGCTGCAGAGGAT-3⬘), shIRF-53 (5⬘-GGCCAAGGAGACAGGGAAA-3⬘), and shIRF-54 (5⬘-CGAGAGAAGAAGCTCATTA-3⬘) were all cloned in the pHP vector, an
shRNA expression plasmid (24). The shIRF4UTR was the mixture of shIRF4UTR5 and shIRF4UTR3 at a 1:1 ratio. The
shIRF-5 could be shIRF-51 plus shIRF-53 or shIRF-52 plus
shIRF-54 at a 1:1 ratio. In our system, we found the combination of two or more shRNAs was more effective in target gene
reductions. IRF-5 antibody (10547-1-AP) was purchased from
Proteintech Group. IRF-4 (28696), PARP (F-2), and GAPDH
(0411) antibodies were purchased from Santa Cruz Biotechnology. Tubulin antibody was purchased from Sigma (T6557).
Caspase 3 antibody was purchased from Imgenex (IMG-144K).
Cell Culture, Transient Transfection, and Isolation of Transfected Cells—DG75 is an EBV-negative Burkitt lymphoma cell
line (25). IB4, Sav I, Sav III, and P2 are all EBV-transformed B
cell lines (26 –28). These cells were maintained in RPMI 1640
medium plus 10% fetal bovine serum (FBS). Electroporation
(320 V; 925 microfarads) was used for transfection of IB4,
DG75, and P2 cells and the isolation of CD4-positive cells with
the use of Dynabeads CD4 (Dynal Inc) as described previously
(29 –31). 293T cells are a human fibroblast line and were maintained in DMEM plus 10% FBS. Effectene (Qiagen) was used for
the transfection of these cells.
Transfection of IB4 Cells for Cell Growth Assays—Transfection of IB4 cells was achieved by using a nucleofector device
from Amaxa. 1 ⫻ 106 cells were transfected with 5 g of DNA in
solution B and program U20. Transfected cells were immediately put into 12-well plates with RPMI 1640 medium plus 20%
FBS. After transfection by using Amaxa transfection apparatus,
⬃50% of cells were dead. The growth rates of cells after transfection were slower than untransfected cells, regardless of plasmid used. Approximately 70% of remaining live cells could be
transfected with the protocol. One day later, live cells were isolated by Ficoll-Paque Plus (GE Healthcare). The live cells were
counted and dispensed in a culture flask at 2 ⫻ 105 cells/ml in
RPMI 1640 medium plus 10% FBS; this was counted as day 1
after transfection. Every day, a small portion of cells were
stained with trypan blue, and live cells were counted using a
hemocytometer.
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DNA Fragmentation Assay and Apoptosis Inhibitors—On
day 3, the same volumes of cells were pelleted, and DNA isolation was performed as described previously (32). The isolated
DNA was separated on an agarose gel. N-Acetylcysteine was
from Sigma (A7250). Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)fluoromethyl ketone) was from R&D
Systems (FMK001), and DMSO was purchased from Sigma
(D2650).
Biotinylated Oligonucleotide Pulldown Assay—The assays
were essentially following the published protocols with 600 g
of lysates (23, 33). Some samples also included 50 g of nonlabeled competitors or poly(dI:dC) (Sigma, P4929). For PV3 promoter binding assays, biotinylated oligonucleotide sequences
were IRF5ISRE-Bf, 5⬘-biotin-GGAGGCTGGGGCAGAAAGCGGAACTGAGCCCGC-3⬘, and IRF5ISRE-Br, 5⬘-biotin-GCGGGCTCAGTTCCGCTTTCTGCCCCAGCCTCC-3⬘. Biotinylated oligonucleotide sequences for mutated PV3 ISRE were
IRF5-ISRE-MBf 5⬘-biotin-GGAGGCTGGGGCAGAAGCCGGAACTGAGCCCGC-3⬘, and IRF-5-ISRE-MBr, 5⬘-biotin-GCGGGCTCAGTTCCGGCTTCTGCCCCAGCCTCC-3⬘. Separation of proteins on SDS-PAGE and Western blot were carried out
following standard protocol as described previously (31, 34).
Chromatin Immunoprecipitation Assay (ChIP)—EZ ChIPTM
chromatin immunoprecipitation kit was used for ChIP assay
following the manufacturer’s recommendations (Millipore;
catalog no. 17-371). 8 g of IRF-4 antibody, normal rabbit
serum, or no antibody was added. 50 ng of DNA were used for
PCR using primers that flank the PV3 or PV1 IRF-binding
sequence region within the two IRF-5 promoters as follows:
IRF5PV3CHIPf, 5⬘-GGGGTCTACAGATACAACTATG-3⬘,
and IRF5PV3CHIPr, 5⬘-GAGAGGTAAGGCCGGCCCTTGC3⬘; IRF5PV1CHIPf, 5⬘-GGGTGACAGAGCAAGACTCC-3⬘,
and IRF5PV1CHIPr, 5⬘-GTCAACAGGCAGCAGGTGTA-3⬘.
Detection of IRF-5 Promoter Usages—Primer sets that specifically recognize IRF-5 promoter regions (promoter V1 specific,
5⬘-CCTGGCGCAGCCACGCAGGCGCA-3⬘, and V3 specific,
5⬘-CTAGGCAGGTGCAACCCCAAAA-3⬘) and a common
region in exon 4 of IRF-5 (5⬘-CCAAAAGAGTAATCCTCAGGG-3⬘) were used for detection of the promoter usages in
target cells (23). Total RNA was isolated; cDNA was synthesized with random hexamers and subjected to PCR analysis
with the promoter specific pairs. The PCR products were electrophoresed on an 8% polyacrylamide gel.

RESULTS
IRF-4 Negatively Regulates the Expression of IRF-5 in EBVtransformed Cells—IRF-5 is a pro-apoptotic gene that is highly
expressed in EBV-transformed cells (35), and we suspect that
IRF-4 might be required for the inhibition of the pro-apoptotic
functions of IRF-5 in EBV transformation. We thus examined if
the expression of IRF-5 is affected by the IRF-4 knockdown in
EBV-transformed cells. IB4, a prototypical cell line transformed
by EBV in vitro (28, 36 – 40), was used for our experiments as it
has a relatively high transfection efficiency with Amaxa technology. As shown in Fig. 1, IRF-4 knockdown resulted in the
increase of IRF-5 protein (lanes 1 and 2). To examine the role of
IRF-4 further, we examined if ectopic expression of IRF-4
affected the expression of IRF-5. IB4 cells were transfected with
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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FIGURE 1. IRF-4 negatively regulates IRF-5 expression. IB4 cells were transfected with shLuc (5 g), shIRF-4 (shIRF-41/shIRF-42/shIRF-43, 1:1:1 ratio, 5
g), pcDNA3 (5 g), or IRF-4 expression plasmid (1 g) by use of a nucleofector device from Amaxa. Total DNA were normalized to 5 g with vector DNA.
Cells were collected 3 days later. The expression levels of IRF-4, IRF-5, and
GAPDH were examined by Western blots. The identities of the proteins are
shown. The images in the same box indicate that they are derived from the
same membrane.

IRF-4 expression plasmid. Overexpression of IRF-4 reduced the
expression of IRF-5 (Fig. 1, lanes 3 and 4). Of note, the exposure
times for the two panels were different. Minimum exposure was
used to show the increase, and moderate exposure time was
used for observation of inhibition. Collectively, those data suggest that IRF-4 negatively regulates IRF-5 expression.
Restoration of IRF-4 Expression Rescues EBV-transformed
Cells from Growth Inhibition—To further evaluate the role of
IRF-4 in the cellular growth of EBV-transformed cells, we have
established a system to specifically knockdown the endogenous
IRF-4 but allow the expression of exogenously introduced
IRF-4. We have chosen the 5⬘- and/or 3⬘-untranslated region
(UTR) of IRF-4 mRNA as targets of shRNA (Fig. 2A).
The shIRF4UTR expression plasmids (the combination of
shIRF4UTR5 and shIRF4UTR3; Fig. 2A) were able to knock
down IRF-4 expression in IB4 cells with the established transfection methods (Fig. 2B). The expression plasmid for IRF-4
was made only using the IRF-4 coding sequences with FLAG tag
on the N terminus (Fig. 2A). Because there is no overlap
between shIRF4UTR target sequences and IRF-4 coding
sequences, the shIRF4UTR does not affect the expression of the
IRF-4 derived from the expression vector. As expected, the
IRF-4 expression was restored in shIRF4UTR ⫹ F-IRF-4 transfected cells (Fig. 2B). In addition, the cell growth of IRF-4-restored cells behaved similarly to the vector control cells (Fig.
2C). These data confirmed that IRF-4 is responsible for the
growth inhibition in EBV-transformed cells. Furthermore, the
expression of IRF-5 was induced when IRF-4 was knocked
down (Fig. 2B, lanes 1 and 2) but reduced upon restoration of
IRF-4 (lanes 3 and 4). Thus, the growth phenotype of IRF-4
knockdown cells was associated with IRF-5 regulation.
IRF-4 Binds to IRF-5 Promoter—IRF-5 has at least two promoters (PV1 and PV3) (23). Both promoters are active in virally
transformed cells (Fig. 3A and supplemental Fig. 1A), and both
have putative IRF-binding sites. Because IRFs can bind to the
same or similar DNA sequences through the conserved DNAbinding domain, we thus suspect that IRF-4 may bind to the
IRF-5 promoter region. To test whether IRF-4 binds the IRF-5
promoter DNA in vivo, ChIP assays were performed with IB4
MAY 20, 2011 • VOLUME 286 • NUMBER 20

FIGURE 2. Restoration of IRF-4 alleviates endogenous IRF-4 knockdownmediated cell growth inhibition. A, schematic diagram of shIRF4UTR and
expression plasmid. The target of the shIRF4UTR is shown. The expression
plasmid was made with just the IRF-4 ORF region. B, restoration of IRF-4 in
endogenous IRF-4 knockdown cells. IB4 cells were transfected with shLuc (4
g), shIRF4UTR (shIRF4UTR5 ⫹ shIRF4UTR3; 4 g), or shIRF4UTR plus F-IRF-4
(1 g) by use of a nucleofector device from Amaxa. Total DNAs were normalized to 5 g with vector DNA. The lanes 3 and 4 represent duplication. The
expression levels of IRF-4, IRF-5, and GAPDH were examined by Western blots.
The images in the same box indicate that they are derived from the same
membrane. C, restoration of IRF-4 rescues cells from growth inhibition. One
day (D) after transfection, live cells were isolated through Ficoll-Paque Plus
and seeded onto fresh media. At the indicated days after transfection, surviving cells were enumerated by trypan blue exclusion. Each point represents
the number of live cells (means ⫾ S.D.) from three different counts. One representative from three independent experiments is shown.

cell lysates, and the region around putative IRF-binding sites
was used as target for amplifying DNA from the immunoprecipitates. As shown in Fig. 3B, the PV3 promoter region was
amplified from immunoprecipitates when IRF-4 antibody was
used (lane 2). However, PCR amplification failed to generate
target DNA from the immunoprecipitates by normal rabbit
antibody (Fig. 3B, lane 3) or without antibody addition (lane 4).
Amplifications of a small fraction of input DNA before immunoprecipitations as well as positive control produced a target
band at the expected size (Fig. 3B, lanes 1 and 5). The data
suggest that IRF-4 binds to IRF-5 promoter regions in vivo.
We further tested whether IRF-4 binds to the IRF-5 promoter by DNA affinity binding assays with extracts from IB4
cells. The biotinylated IRF-5 PV3 ISRE was used to pull down
the binding proteins, and various combinations of other
annealed oligonucleotides were used as competitors. As shown
in Fig. 3C, IRF-4 did bind to DNA (lane 1). The IRF-4 binding
was competed out by incubating with nonbiotinylated wild type
PV3 ISRE (Fig. 3C, lane 2). In contrast, mutated PV3-ISRE,
nonrelevant Zta-response element, and poly(dI:dC) did not
compete for IRF-4 binding (Fig. 3C, lanes 3–5). The residual
carry-over GAPDH was used as an internal control for affinity
binding assays. A small fraction of input IB4 cell lysates was also
shown (Fig. 3C, lane 6). The mutated ISRE seemed to bind to
IRF-4 also in a less efficient manner in this assay, possibly due to
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 4. IRF-4 negatively regulates IRF-5 promoter activity. A, IRF-4
represses IRF-5 promoter reporter activity. 293T cells were transfected with
various reporter constructs and expression plasmid (0.01, 0.05, and 0.1 g) as
shown at the top. The mPV3-luc has the IRF-5 ISRE sequences mutated in the
ISRE in the promoter reporter construct. Cell lysates were used for the luciferase and ␤-galactosidase assays. Relative promoter reporter activities (luciferase/␤-galactosidase) are shown. Standard error bars are shown. B, endogenous IRF-4 regulates IRF-5 promoter activity. IB4 cells were transfected with
the indicated plasmid as shown at the top. shIRF4UTR and F-IRF-4 usages
were the same as in Fig. 2. Two days later, luciferase and ␤-galactosidase
activities were measured. Relative promoter reporter activities are shown.
FIGURE 3. IRF-4 binds to IRF-5 promoter region. A, PV3 promoter is active in
EBV-transformed cells. The RNAs were isolated from the EBV-transformed
cells as shown at the top, and RT-PCR was used to determine the transcriptional activities with the target PV3 promoter-specific primers. The specific
promoter usage, and specificity of the amplification, is indicated. B, IRF-4
binds to IRF-5 promoter in vivo. IRF-4 antibody (Ab) was used for ChIP analyses
to detect in vivo DNA binding activities to the IRF-5 promoter region. Primers
for IRF-5 PV3 promoter regions surrounding the putative IRF-4-binding site
were used to amplify the DNA from immunoprecipitates. The identity of IRF4-bound, PV3 promoter amplification is as shown. The plasmid, IRF-5 PV3-luc,
was used as positive control. Input DNA represents the PCR amplification
from 1/100th the amount of input lysates for immunoprecipitations. PCR
amplification of immunoprecipitates from normal rabbit serum is also shown
as control. C, IRF-4 binds to the IRF-5 promoter in vitro. Cell extracts were
made from IB4 cells and incubated with biotinylated oligonucleotides containing the IRF-5 PV3 ISRE sequences. The un-biotinylated IRF-5 PV3 ISRE, PV3
mISRE, Zta-response element oligonucleotides, or poly(dI:dC) were used as
competitors as shown at the top. 1/20th of input cell lysates for pulldown
experiments was used as a control. Western blots were carried out for the
detection of IRF-4 and GAPDH.

the specificity of IRF-4 and the IRF-5 PV3 ISRE, and/or the
oligonucleotide pulldown assay itself (supplemental Fig. 1D).
IRF-4 is also able to bind to PV1 promoter (supplemental Fig. 1,
B and C). In summary, these results suggest that IRF-4 is able to
bind IRF-5 promoter.
IRF-4 Represses IRF-5 Promoter Activity—Once the IRF-4
binding to IRF-5 PV3 promoter was established, we examined if
IRF-4 could repress the IRF-5 promoter reporter constructs as
IRF-4 is predominantly a transcriptional repressor (10, 11).
Both PV1 and PV3 promoter luciferase reporter constructs
were used. The promoter reporter construct and IRF-4 expression plasmid were co-transfected into 293T cells, and the
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reporter activities were measured. As shown in Fig. 4A, IRF-4
was able to repress the IRF-5 PV3 promoter reporter construct.
However, IRF-4 failed to repress the reporter construct with
ISRE mutations, which correlates with that data that IRF-4
binds to mutated ISRE less efficiently. Interestingly, IRF-4 failed
to repress the PV1 reporter construct in this assay (supplemental Fig. 1E).
Furthermore, we tested if the endogenous IRFs affected
IRF-5 PV3 promoter activities. The shIRF-4 and other plasmids
were transfected into IB4 cells, along with the promoter
reporter construct. As shown in Fig. 4B, shIRF4UTR up-regulated the IRF-5 PV3 promoter reporter activities and co-transfection with IRF-4 repressed the activity. In addition, mutated
ISRE PV3 promoter (mPV3-luc) barely responded to
shIRF4UTR expression. The IRF-5 PV1 promoter reporter construct had hardly any detectable activities in IB4 cells (data
not shown). We used the conditional medium from shLuc- or
shIRF4UTR-transfected IB4 cells and the treated 293T cells transfected with IRF-5 promoter construct (PV3-Luc). The conditional
medium did not have an impact on the promoter reporter activity
of PV3 (supplemental Fig. 2A). In addition, similar results to Fig.
4B can be obtained in P2 cells, a STAT-1-null EBV-transformed
cell line (supplemental Fig. 2B) (26). Therefore, the potential
inflammatory cytokines induced by shRNAs were probably not
responsible for the activation of PV3 promoter reporter in IB4
cells. All these results collectively suggest that IRF-4 represses
IRF-5 PV3 promoter reporter construct.
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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Knockdown of IRF-5 Rescues IRF-4 Knockdown-mediated
Growth Inhibition—Next, we examined the role of IRF-5 in
EBV-transformed cells. IRF-5 is considered as a tumor suppressor. The shIRF-5 plasmids were transfected into IB4 cells, and the
knockdown of IRF-5 greatly enhanced the growth of EBV-transformed cells (Fig. 5A). Reduction of IRF-5 was confirmed by Western blot (Fig. 5B). Thus, the physiological levels of IRF-5 were able
to repress cellular growth in EBV-transformed cells.

FIGURE 5. Knockdown of IRF-5 rescues IRF-4 knockdown-mediated
growth inhibition. A, IB4 cells were transfected with shLuc (5 g; line ⫹),
shIRF-4 (shIRF-41 ⫹ shIRF-42 ⫹ shIRF-43, 1:1:1 ratio, 2.5 g; line *), shIRF5
(shIRF-51 ⫹ shIRF-53, 1:1 ratio, 2.5 g; solid square), shIRF4 plus shIRF-5
(shIRF-51 ⫹ shIRF-53; open square), shIRF-5 (shIRF-52 ⫹ shIRF-54, 1:1 ratio, 2.5
g; solid circle), or shIRF-4 plus shIRF-5 (shIRF-52 ⫹ shIRF-54; open circle) by
Amaxa nucleofector technology. Total DNA was normalized to 5 g with
shLuc DNA. One day (D) after the transfection, live cells were isolated. At the
indicated days after transfection, surviving cells were enumerated. Each point
represents the number of live cells (means ⫾ S.D.). The use of shIRF52 plus
shIRF-54 also produced curative data. Results from one representative experiment are as shown. B, expression levels of the various proteins. IB4 cells were
transfected with various plasmids as shown at the top. The expression
levels of IRF-4, IRF-5, and GAPDH were examined by Western blots 2 days
after transfection. The identities of the proteins are shown.

Whether the knockdown of IRF-5 alleviates the IRF-4,
knockdown-mediated growth inhibition was examined. As
shown in Fig. 5A, shIRF-4 represses the cell growth as shown
before. However, when shIRF-5 and shIRF-4 were co-transfected,
the growth inhibition of shIRF-4 was partially alleviated (open circle and square). This suggests that IRF-5 is one of the targets for
IRF-4 in the regulation of cellular growth in EBV-transformed
cells.
Caspase Inhibitor Rescues IRF-4 Knockdown-mediated Cell
Growth Inhibition—To evaluate the role of apoptosis in IRF-4
knockdown-mediated growth inhibition, we used caspase inhibitors to block the caspase dependent apoptosis. IB4 cells
were transfected with shLuc or shIRF-4. One day after the
transfection, live cells were isolated, seeded, and treated with
DMSO, Z-VAD-FMK (20 M), or NAC (10 mM), respectively.
Z-VAD-FMK is a pan-caspase inhibitor that irreversibly binds
to the catalytic site of caspase proteases and can inhibit induction of apoptosis. At lower concentrations, NAC is nontoxic to
cultured cells and can protect against apoptosis induced by
intracellular reactive oxygen species. As shown in Fig. 6A,
Z-VAD-FMK almost completely recovered the IRF-4 knockdown-mediated cell growth inhibition but NAC did not (Fig.
6A). As expected, DMSO has no effect on cellular growth, and
no drugs have an effect on shLuc-transfected cells (Fig. 6A, right
panel). It is known that IRF-4 knockdown leads to caspase 3
activation (data not shown) (7). Thus, it is likely that caspasedependent apoptosis is the major factor affecting IRF-4 knockdown-mediated growth inhibition.
Overexpression of IRF-5 Inhibits Cellular Growth in EBVtransformed Cells—Because of the facts that IRF-4 knockdown
inhibited the cellular growth and induced IRF-5 expression,
whether IRF-5 overexpression itself is able to cause inhibition

FIGURE 6. Caspase inhibition prevents IRF-4 knockdown-mediated growth inhibition. A, caspase inhibition and cell growth. IB4 cells were transfected with
5 g of shLuc (right panel) or shIR-F4 (shIRF-41 ⫹ hIRF-42 ⫹ shIRF-43, 1:1:1 ratio) (left panel). One day (D) after the transfection, live cells were isolated through
Ficoll-Paque Plus. The cells were seeded at desired concentrations in different wells with no treatment or with treatment of DMSO, Z-VAD (20 M), or NAC (10
mM). At the indicated days after treatment, surviving cells were enumerated. Each point represents the number of live cells (mean ⫾ S.D.). B, overexpression of
IRF-5 inhibits cell growth of EBV-transformed cells. One day after the transfection, live cells were isolated. At the indicated days after transfection, surviving cells
were enumerated. Each point represents the number of live cells (mean ⫾ S.D.). C, protein cleavage in IRF-5-overexpressing cells. Lysates from transfected cells
at day 3 were used for Western blot analysis with PARP, IRF-5, caspase 3, and GAPDH antibodies. The molecular masses (kDa) of PARP fragments are indicated
in parentheses. The images in the same box are derived from the same membrane. The identities of the proteins are as shown. D, DNA fragmentation in
IRF-5-transfected cells. Total cellular DNAs were isolated on day 3. The sizes of the DNA markers are as shown on the left in base pairs.
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of cell growth was examined. IRF-5 expression plasmid (splicing variant 4) was transfected into IB4 cells, and the cell growth
was monitored on a daily basis. As shown in Fig. 6B, the IRF-5transfected cells had a much slower growth rate. The reason to
use the IRF-5 splicing variant 4 in this experiment is that the
variant has a similar property to other splicing variants as a
full-length protein, and the variant was the first to be cloned
and the most extensively characterized splicing variant of
IRF-5. Furthermore, hallmarks of apoptosis were examined.
We found that IRF-5 induced the cleavage of PARP and caspase
3, as well as the DNA fragmentation; those markers are indicative of apoptosis (Fig. 6, C and D). Of note, IRF-5 is predominantly localized in the cytoplasm in EBV-transformed cells
(supplemental Fig. 3), but IRF-5 seems to be functional as
endogenous levels of IRF-5 inhibit cell growth (Fig. 5). Therefore, IRF-5 overexpression inhibits cellular growth, partially
through induction of apoptosis.

DISCUSSION
The involvement of IRFs in oncogenesis has been extensively
studied. Previously, we have established that IRF-4 is involved
in the EBV-mediated transformation process in vitro and possibly in vivo for lymphoma in the central nervous system (7). In
this study, we have uncovered a novel mechanism for IRF-4 to
regulate EBV-mediated cellular growth, i.e. by repressing the
expression of IRF-5, a pro-apoptotic member of IRFs.
We have demonstrated the following. First, IRF-5 is induced
once IRF-4 is down-regulated (Figs. 1 and 2B), and the restoration of IRF-4 by exogenous plasmids reduces IRF-5 expression
(Fig. 2B). Moreover, overexpression of IRF-4 represses IRF-5
expression (Fig. 1). Second, IRF-4 binds to IRF-5 promoter
regions. IRF-5 has at least two promoters (PV1 and PV3) that
are active in EBV-transformed cells. Both promoters have putative IRF-binding sites, and IRF-4 binds to the PV3 promoter in
vivo and in vitro (Fig. 3 and supplemental Fig. 1). Third, IRF-4
represses the IRF-5 PV3 promoter reporter construct (Fig. 4A),
and the PV3 promoter reporter construct behaves just like the
IRF-5 protein in EBV-transformed cells (Fig. 4B). Interestingly,
IRF-4 did not repress the IRF-5 PV1 reporter construct in our
experimental settings (supplemental Fig. 1E). Therefore, IRF-5
is apparently a target of IRF-4 at the PV3 promoter level in
EBV-transformed cells. It is of note that IRF-4 itself has marginal effects on the IRF-5 promoter reporter (Fig. 4A), but in the
context of EBV latency, IRF-4 seems to have a stronger effect
(compare Fig. 4, A and B). The large increase of IRF-5 luciferase
activity in IB4 cells might be related to the fact that IRF-4 has
multiple targets, and some of the targets may also be involved in
the regulation of IRF-5 expression.
The regulation of IRF-5 by IRF-4 may be related to the biological function of IRF-4 in the regulation of cell growth in EBV
transformation. First, knockdown of IRF-4 inhibits the growth
properties of transformed cells (Figs. 2C and 5A), and the inhibition of cell growth is positively associated with IRF-5 up-regulation (Figs. 1 and 2). Second, supplement of endogenous
IRF-4 with plasmid-derived IRF-4 restores the growth of transformed cells and the down-regulation of IRF-5 (Fig. 2). Third,
IRF-5 itself is a pro-apoptotic factor. IRF-5 seems to inhibit cell
growth at the physiological levels (Fig. 5A), and overexpression
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of IRF-5 in EBV-transformed cells inhibits cell growth, at least
partially through apoptosis induction (Fig. 6, B–D). Fourth,
knockdown of IRF-5 rescues IRF-4 knockdown-mediated
growth inhibition (Fig. 5A). Fifth, IRF-4 knockdown-mediated
growth inhibition is mainly through the caspase-dependent
apoptotic pathway (Fig. 6A), which correlates IRF-5 induction
and the induction of apoptosis by IRF-5 (Figs. 1, 2, and 6, C and
D). Sixth, and finally, the inhibition of cell growth by IRF-4 is
not restricted to IB4 cells, other EBV-transformed cells were
also inhibited by shIRF-4 transfection (supplemental Fig. 4).
Interestingly, the EBV-negative Burkitt lymphoma line, DG75,
IRF-4 has limited effects, suggesting IRF-4 might be preferentially playing a critical role in EBV-transformed cells (supplemental Fig. 4).
Of note, two sets of shIRF-5 (shIRF-51 plus shIRF-53 or
shIRF-52 plus shIRF-54) generated similar results (Fig. 5A),
suggesting the off-target effects of shIRF-5 are minimal. In
addition, the off-targeting and other nonspecific effects of the
shIRF-4 may be minimal (7). We also show that the other sets of
shIRF-4 are able to reduce the expression of endogenous IRF-4.
Furthermore, the restoration of IRF-4 by exogenous plasmids
restored the growth properties of EBV-transformed cells (Fig.
2). IRF-4 is therefore a critical factor in EBV transformation by
blocking the IRF-5-mediated apoptosis processes.
EBV activates many pro-apoptotic (such as p53) and antiapoptotic (such as Bcl-2) factors during transformation processes (41, 42). EBV also encodes anti-apoptotic genes, such as
latent membrane protein 1 and two viral Bcl-2 homologous
genes (6, 43– 45). IRF-5 is one of the pro-apoptotic gene products induced by EBV. It is apparent that the physiological levels
of IRF-5 are involved in the growth of EBV-transformed cells
(Fig. 5). Thus, EBV must use another gene(s) to block such
pro-apoptotic action of IRF-5. IRF-4 is clearly a candidate for
this purpose. Other than repressing the expression of IRF-5,
IRF-4 may regulate IRF-5 targets directly. It is known that IRF-4
binds to MyD88, competes with IRF-5, and negatively regulates
IRF-5-mediated activation of proinflammatory cytokines (17).
In addition, IRF-4 may inhibit IRF-5-mediated activation of
certain genes by competing for binding to promoter regions as
IRF-binding sites are similar.
It is interesting that both IRF-4 and IRF-5 are highly
expressed in EBV-transformed cells (35). Therefore, it is apparent that EBV uses IRF-4 to prevent a super-activation of IRF-5
during EBV transformation. The reciprocal inhibition and/or
activation between the two factors may contribute to apoptosis
or proliferation in infected cells. EBV may use this dynamic
equilibrium for its own benefit in various microenvironments
for the survival of the virus in vivo. It is suspected that the ratio
of IRF-1 (a tumor suppressor)/IRF-2 (an oncogene) is important in certain tumor development (46 – 48). Here, we have provided another possible scenario that two IRFs may regulate cell
growth in a different setting.
Apparently oncogenic herpesviruses and IRFs have intimate
connections. EBV has been known to have an intimate relation
with IRF-7 (29, 34, 49, 50). The genome of Kaposi sarcomaassociated herpesvirus contains several homologous IRFs
(vIRFs) (51–53). Kaposi sarcoma-associated herpesvirus is
implicated in the pathogenesis of Kaposi sarcoma, primary
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effusion lymphoma, and multicentric Castleman disease (51,
54, 55). Rhesus rhadinovirus, another oncogenic herpesvirus,
has eight vIRFs in the genome (56, 57). In this study, we have
identified a novel mechanism that IRF-4 regulates cellular
growth by targeting pro-apoptotic IRF-5 during EBV transformation. The modulation of IRF pathway is apparently a common theme used by oncogenic herpesviruses.
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Supplemental Figure 1: IRF-4 binds to IRF-5 PV1 promoter region. A) The PV1 promoter is active
in EBV transformed cells. The RNAs were isolated from the EBV transformed cells as shown on the top,
and RT-PCR was used to determine the transcriptional activities with the target promoter-specific
primers. The specificity of the amplification is indicated. B) IRF-4 binds to IRF-5 PV1 promoter in vivo.
IRF-4 antibody was used for ChIP analyses to detect in vivo DNA binding activities to IRF-5 promoter
region. Primers for IRF-5 PV-1 promoter regions were used to amplify the DNA from
immunoprecipitates. The identity of PV1-promoter amplification is as shown. The plasmid, IRF-5 PV1-luc,
was used as positive control. Input DNA represents the PCR amplification from 1/100 the amount of
input lysates for immunoprecipitations. PCR amplification of immunoprecipitates from normal rabbit
serum (NRS) is also shown as controls. C) IRF-4 binds to PV-1 promoter in vitro. Cell extracts were
made and from IB4 cells and incubated with biotinylated oligonucleotides containing the IRF-5 PV-1
IRF-E sequences with or without the un-biotinylated IRF-5 PV1 IRF-E, or poly(dI-dC) as competitors.
Western blots were carried out for the detection of IRF-4. D). IRF-4 binds to IRF-5 mutated ISRE weakly
in vitro. Cell extracts were made and from IB4 cells and incubated with biotinylated oligonucleotides
containing the IRF-5 PV-3 ISRE sequences or its mutated conyterparts. Western blots were carried out
for the detection of IRF-4 and GAPDH. E). IRF-4 did not repress IRF-5 PV-1 promoter activity. 293T
cells were transfected with various reporter constructs and expression plasmid (0.01, 0.05, and 0.1 g) as
shown on the top. Cell lysates were used for the luciferase and -galactosidase assays. Relative promoter
reporter activities (luciferase/ -galactosidase) are shown. Standard error bars are shown.
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Supplenmenatl Figure 2:
A. Conditional medium from shIRF-4-transfected cells did not activate PV-3 promoter reporter
construct. IB4 cells were transfected with shLuc or shIRF4. The medium was collected and passed
through a 0.2 mm filter . The conditional medium was used for the treatment. 293T cells were
transfected with PV-3 reporter construct for one day. The conditional medium was added (1:1 ratio)
as shown on the top. Cell lysates were used for the luciferase and -galactosidase assays one day later.
shIRF4 was duplicated.
B. Endogenous IRF-4 regulates IRF-5 promoter activity in P2 cells. P2 are STAT-1-null
EBV-transformed B lymphocyte line. P2 cells were transfected with indicated plasmid as shown on the
top. Two days later, luciferase and -galactosidase activities were measured. Relative promoter reporter
activities are shown.
C. Caspase 3 cleavage in IRF-4-knockdown cells. IB4 cells were transfected with shLuc or shIRF4.
Two days later, lysates from transfected cells were used for western blot analysis with caspase 3
antibody. shIRF4 was duplicated. The identity of proteins is as shown.
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Supplemental Figure 3. A. Subcellular localization of IRF-5. Cells were stained with
anti-IRF-5 and AlexaFlor 488-labeled secondary antibodies were used to determine the
subcellular localization of IRF-5 (green). DAPI was used to stain the nuclei (blue). Sav I
and Sav III are gentically identical cell lines with different EBV latencies. It is known that
IRF-5 is expressed at high levels in type III latency. IB-4 is a type III latency cells.
B. Reduction of IRF-5 reduces the expression of Bax. IB4 cells were transfected
with shLuc or shIRF5 . Two days after transfection, cells were collected and western
blot was used to examine the expression .
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Supplemental Figure 4. Knockdown of IRF-4 inhibits cell growth of EBV-transformed cells.
A) Knockdown of IRF-4 inhibits cell growth of P2 cells. P2 is an EBV-transformed cell line. P2 cells were
transfected with shLuc (5 μg), shIRF4 (5 μg) along with CD4 expression plasmid (1μg). One day after the
transfection, CD4 expression cells were enriched with a magnetic beads containing CD4 antibody
(In vitrogen). At the indicated days after transfection, surviving cells were enumerated. Each point
represents the number of live cells (mean ± S.D.). One representative from three independent
experiments is shown. B. Knockdown of IRF-4 does not inhibit cell growth of DG75 cells. DG75 is an
EBV-negative BL cell line. Similar methods were used as in P2 cells. The expression of IRF-4 in P2 cells (C),
or in DG75 cells (D) are shown. The images in the same box are derived from the same membrane.

